La presente invención se refiere a nuevos compuestos de la fórmula (1) o sal, solvato o estereoisómero farmacéuticamente aceptables de los mismos, que tienen propiedades inhibidoras del EGFR, a las composiciones farmacéuticas que contienen dichos compuestos, a los métodos de tratamiento de enfermedades o trastornos y al uso de dichos compuestos como productos farmacéuticos para tratar enfermedades o trastornos. Reivindicación 1: Un compuesto de fórmula (1) o a una sal, un solvato o un estereoisómero del mismo farmacéuticamente aceptable, donde L¹ es un enlace químico o -NH-; X¹ es -CH-, -N- o bien -C(R⁶)-; cada n, m es independientemente 0, 1, 2, 3 ó 4; cada R¹ es independientemente -H; -Hal; -C(Hal)₃; -CN; -NR⁷R⁸; -C(O)NR⁹R¹⁰; -C(O)OR¹¹; -C(O)R¹²; -OR¹³; -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales R¹⁴; -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R¹⁴ᵃ; R² es -P(O)((C₁-C₆)alquilo)₂, sin sustituir o sustituido por uno o varios radicales R¹⁵; -P(O)((C₃-C₆)cicloalquilo)₂, sin sustituir o sustituido por uno o varios radicales R¹⁵ᵃ; -P(O)((C₁-C₆)alquilo)((C₃-C₆)cicloalquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵ᵇ; -P(O)(O(C₁-C₆)alquilo)₂, sin sustituir o sustituido por uno o varios radicales R¹⁵ᶜ; -P(O)(O(C₃-C₆)cicloalquilo)₂, sin sustituir o sustituido por uno o varios radicales R¹⁵ᵈ; -P(O)(O(C₁-C₆)alquilo)(O(C₃-C₆)cicloalquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵ᵉ; P(O)(O(C₁-C₆)alquilo)((C₃-C₆)cicloalquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵; -P(O)(O(C₁-C₆)alquilo)((C₁-C₆)alquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵; -P(O)(O(C₃-C₆)cicloalquilo)((C₁-C₆)alquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵; -P(O)(O(C₃-C₆)cicloalquilo)((C₃-C₆)cicloalquilo), sin sustituir o sustituido por uno o varios radicales R¹⁵; -SO₂(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales R¹⁵ᶠ; o -SO₂(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R¹⁵ᵍ; R³ es -H; -Hal; -CN; -C(Hal)₃; -NR⁷ᵃR⁸ᵃ; -C(O)NR⁹ᵃR¹⁰ᵃ; -C(O)OR¹¹ᵃ; -C(O)R¹²ᵃ; -OR¹³ᵃ; -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales R¹⁶ᵃ; -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R¹⁶ᵇ; -(C₆-C₁₂)arilo, sin sustituir o sustituido por uno o varios radicales R¹⁶ᶜ; heteroarilo de 4 a 10 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, sin sustituir o sustituido por uno o varios radicales R¹⁶ᵈ; cada R⁴ es independientemente -H; -Hal; -CN; -NR⁷ᵇR⁸ᵇ; -C(Hal)₃; -C(O)NR⁹ᵇR¹⁰ᵇ; -C(O)OR¹¹ᵇ; -C(O)R¹²ᵇ; -OR¹³ᵇ; -(C₁-C₆)alquilo, no sustituido o sustituido por uno o varios radicales R¹⁷ᵃ; -(C₃-C₆)cicloalquilo, no sustituido o sustituido por uno o varios radicales R¹⁷ᵇ; heterociclilo de 4 a 10 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, no sustituido o sustituido por uno o varios radicales R¹⁷ᶜ; o -(C₆-C₁₂)arilo, no sustituido o sustituido por uno o varios radicales R¹⁷ᵈ; R⁵ es: -NR⁷ᶜR¹⁸; -NR⁷ᵈR¹⁹; -W¹; -OW²; -NRᵃW³; -C(O)W⁴; o bien -(CH₂)W⁵; donde cada W¹, W², W³, W⁴ o W⁵ es independientemente -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R²⁰; heterociclilo de 4 a 7 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, sin sustituir o sustituido por uno o varios radicales R²⁰, R⁶ es -Hal, -CN, -C(Hal)₃, CH(Hal)₂, CH₂Hal, -NR⁷ᵉR⁸ᶜ; -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O); cada R⁷, R⁷ᵃ, R⁷ᵇ, R⁷ᵉ, R⁸, R⁸ᵃ, R⁸ᵇ, R⁸ᶜ, R⁹, R⁹ᵃ, R⁹ᵇ, R¹⁰, R¹⁰ᵃ, R¹⁰ᵇ es independientemente -H, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O) -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O); cada R⁷ᶜ, R⁷ᵈ, Rᵃ es independientemente -H, -(C₁-C₆)alquilo; R¹⁸ es -(C₁-C₁₀)alquilo, sin sustituir o sustituido por uno o varios sustituyentes seleccionados entre -Hal, -OH, -NO₂, -NR²³R²⁴, (=O); R¹⁹ es un heteroalquilo de 2 a 10 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, sin sustituir o sustituido por uno o varios sustituyentes seleccionados entre -Hal, -OH, -NO₂, -NR²³R²⁴, (=O); cada R¹¹, R¹², R¹³, R¹¹ᵃ, R¹²ᵃ, R¹³ᵃ, R¹¹ᵇ, R¹²ᵇ, R¹³ᵇ es independientemente -H, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales R²¹, -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R²¹ᵃ, -(C₆-C₁₂)arilo, sin sustituir o sustituido por uno o varios radicales R²¹ᵇ, heterociclilo de 4 de 10 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, sin sustituir o sustituido por uno o varios radicales R²¹ᶜ; cada R¹⁴, R¹⁴ᵃ, R¹⁵, R¹⁵ᵃ, R¹⁵ᵇ, R¹⁵ᶜ, R¹⁵ᵈ, R¹⁵ᵉ, R¹⁵ᶠ, R¹⁵ᵍ, R¹⁶, R¹⁶ᵃ, R¹⁶ᵇ, R¹⁶ᶜ, R¹⁶ᵈ, R¹⁷, R¹⁷ᵃ, R¹⁷ᵇ, R¹⁷ᶜ, R¹⁷ᵈ es independientemente -Hal, -H, -OH, -NO₂, -NR²³R²⁴, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O); cada R²⁰ es independientemente (=O), -NR⁷ᶠR⁸ᵈ, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales R²², heteroalquilo de 2 a 8 miembros con 1 ó 2 heteroátomos seleccionados entre N, O ó S, sin sustituir o sustituido por uno o varios radicales R²²ᵃ, -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales R²²ᵇ, heterociclilo de 4 a 10 miembros con 1 ó 2 heteroátomos seleccionados entre N, S u O, sin sustituir o sustituido por uno o varios radicales R²²ᶜ; cada R⁷ᶠ, R⁸ᵈ es independientemente -H, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O); -(C₃-C₆)cicloalquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -OH, (=O); cada R²¹, R²¹ᵃ, R²¹ᵇ, R²¹ᶜ, R²², R²²ᵃ, R²²ᵇ, R²²ᶜ es independientemente -Hal, -H, -OH, -NO₂, -NR²³R²⁴, -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre -Hal, -NH₂, -O(C₁-C₆)alquilo, -OH, (=O); cada R²³, R²⁴ es independientemente -H; -(C₁-C₆)alquilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre (=O), -OH, -NR²⁵R²⁶; -(C₂-C₆)alquenilo, sin sustituir o sustituido por uno o varios radicales seleccionados entre (=O), -NR²⁵ᵃR²⁶ᵃ; cada R²⁵, R²⁶, R²⁵ᵃ, R²⁶ᵃ es independientemente -H, -(C₁-C₆)alquilo; Hal es un átomo de flúor, bromo, cloro o yodo. Reivindicación 16: Un método de inhibición de la actividad biológica del receptor del factor de crecimiento epidérmico (EGFR) en un sujeto, que consiste en poner en contacto el dominio quinasa del EGFR con un compuesto como se reivindica en cualquiera de las reivindicaciones 1 - 15 o su sal, solvato o estereoisómero farmacológicamente aceptable. Reivindicación 23: Un método de tratamiento de una enfermedad o trastorno mediado por la actividad del EGFR, que incluye la administración en una cantidad terapéuticamente eficaz de un compuesto como se reivindica en las reivindicaciones 1 - 15 o su sal, solvato o estereoisómero farmacológicamente aceptable, o la composición farmacéutica como se reivindica en la reivindicación 17 a un sujeto que necesita dicho tratamiento.The present invention relates to novel compounds of the formula (1) or pharmaceutically acceptable salt, solvate or stereoisomer thereof, having EGFR inhibitory properties, to pharmaceutical compositions containing said compounds, to methods of treating diseases or disorders and the use of such compounds as pharmaceuticals to treat diseases or disorders. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein L¹ is a chemical bond or -NH-; X¹ is -CH-, -N- or -C(R⁶)-; each n, m is independently 0, 1, 2, 3, or 4; each R¹ is independently -H; -Hal; -C(Hal)₃; -CN; -NR⁷R⁸; -C(O)NR⁹R¹⁰; -C(O)OR¹¹; -C(O)R¹²; -OR¹³; -(C₁-C₆)alkyl, unsubstituted or substituted by one or more R¹⁴ radicals; -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more radicals R¹⁴ᵃ; R² is -P(O)((C₁-C₆)alkyl)₂, unsubstituted or substituted by one or more radicals R¹⁵; -P(O)((C₃-C₆)cycloalkyl)₂, unsubstituted or substituted by one or more R¹⁵ᵃ radicals; -P(O)((C₁-C₆)alkyl)((C₃-C₆)cycloalkyl), unsubstituted or substituted by one or more radicals R¹⁵ᵇ; -P(O)(O(C₁-C₆)alkyl)₂, unsubstituted or substituted by one or more radicals R¹⁵ᶜ; -P(O)(O(C₃-C₆)cycloalkyl)₂, unsubstituted or substituted by one or more R¹⁵ᵈ radicals; -P(O)(O(C₁-C₆)alkyl)(O(C₃-C₆)cycloalkyl), unsubstituted or substituted by one or more radicals R¹⁵ᵉ; P(O)(O(C₁-C₆)alkyl)((C₃-C₆)cycloalkyl), unsubstituted or substituted by one or more R¹⁵ radicals; -P(O)(O(C₁-C₆)alkyl)((C₁-C₆)alkyl), unsubstituted or substituted by one or more radicals R¹⁵; -P(O)(O(C₃-C₆)cycloalkyl)((C₁-C₆)alkyl), unsubstituted or substituted by one or more radicals R¹⁵; -P(O)(O(C₃-C₆)cycloalkyl)((C₃-C₆)cycloalkyl), unsubstituted or substituted by one or more radicals R¹⁵; -SO₂(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals R¹⁵ᶠ; or -SO₂(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more radicals R¹⁵ᵍ; R³ is -H; -Hal; -CN; -C(Hal)₃; -NR⁷ᵃR⁸ᵃ; -C(O)NR⁹ᵃR¹⁰ᵃ; -C(O)OR¹¹ᵃ; -C(O)R¹²ᵃ; -OR¹³ᵃ; -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals R¹⁶ᵃ; -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more R¹⁶ᵇ radicals; -(C₆-C₁₂)aryl, unsubstituted or substituted by one or more radicals R¹⁶ᶜ; 4 to 10-membered heteroaryl with 1 or 2 heteroatoms selected from N, S or O, unsubstituted or substituted by one or more R¹⁶ᵈ radicals; each R⁴ is independently -H; -Hal; -CN; -NR⁷ᵇR⁸ᵇ; -C(Hal)₃; -C(O)NR⁹ᵇR¹⁰ᵇ; -C(O)OR¹¹ᵇ; -C(O)R¹²ᵇ; -OR¹³ᵇ; -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals R¹⁷ᵃ; -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more R¹⁷ᵇ radicals; 4 to 10 membered heterocyclyl with 1 or 2 heteroatoms selected from N, S or O, unsubstituted or substituted by one or more R¹⁷ᶜ radicals; or -(C₆-C₁₂)aryl, unsubstituted or substituted by one or more radicals R¹⁷ᵈ; R⁵ is: -NR⁷ᶜR¹⁸; -NR⁷ᵈR¹⁹; -W¹; -OW²; -NRᵃW³; -C(O)W⁴; or -(CH₂)W⁵; where each W¹, W², W³, W⁴ or W⁵ is independently -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more R²⁰ radicals; 4 to 7 membered heterocyclyl with 1 or 2 heteroatoms selected from N, S or O, unsubstituted or substituted by one or more radicals R²⁰, R⁶ is -Hal, -CN, -C(Hal)₃, CH(Hal)₂ , CH₂Hal, -NR⁷ᵉR⁸ᶜ; -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O); each R⁷, R⁷ᵃ, R⁷ᵇ, R⁷ᵉ, R⁸, R⁸ᵃ, R⁸ᵇ, R⁸ᶜ, R⁹, R⁹ᵃ, R⁹ᵇ, R¹⁰, R¹⁰ᵃ, R¹⁰ᵇ is independently -H, -(C₁-C ₆)alkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O) -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O); each R⁷ᶜ, R⁷ᵈ, Rᵃ is independently -H, -(C₁-C₆)alkyl; R¹⁸ is -(C₁-C₁₀)alkyl, unsubstituted or substituted by one or more substituents selected from -Hal, -OH, -NO₂, -NR²³R²⁴, (=O); R¹⁹ is a 2 to 10 membered heteroalkyl with 1 or 2 heteroatoms selected from N, S or O, unsubstituted or substituted by one or more substituents selected from -Hal, -OH, -NO₂, -NR²³R²⁴, (=O); each R¹¹, R¹², R¹³, R¹¹ᵃ, R¹²ᵃ, R¹³ᵃ, R¹¹ᵇ, R¹²ᵇ, R¹³ᵇ is independently -H, -(C₁-C₆)alkyl, unsubstituted or substituted by one or more R²¹, -(C₃-C₆)cycloalkyl radicals, unsubstituted or substituted by one or more radicals R²¹ᵃ, -(C₆-C₁₂)aryl, unsubstituted or substituted by one or more radicals R²¹ᵇ, 4-of-10-membered heterocyclyl with 1 or 2 heteroatoms selected from N, S or O, without substitute or substituted by one or more radicals R²¹ᶜ; each R¹⁴, R¹⁴ᵃ, R¹⁵, R¹⁵ᵃ, R¹⁵ᵇ, R¹⁵ᶜ, R¹⁵ᵈ, R¹⁵ᵉ, R¹⁵ᶠ, R¹⁵ᵍ, R¹⁶, R¹⁶ᵃ, R¹⁶ᵇ, R¹⁶ᶜ, R¹⁶ᵈ, R¹⁷, R¹⁷ᵃ, R¹⁷ᵇ, R¹⁷ᶜ, R¹⁷ᵈ is independently -Hal, -H, -OH , -NO₂, -NR²³R²⁴, -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O); each R²⁰ is independently (=O), -NR⁷ᶠR⁸ᵈ, -(C₁-C₆)alkyl, unsubstituted or substituted by one or more R²² radicals, 2- to 8-membered heteroalkyl with 1 or 2 heteroatoms selected from N, O or S, unsubstituted or substituted by one or more radicals R²²ᵃ, -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more radicals R²²ᵇ, 4 to 10-membered heterocyclyl with 1 or 2 heteroatoms selected from N, S or O, without substitute or substituted by one or more radicals R²²ᶜ; each R⁷ᶠ, R⁸ᵈ is independently -H, -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O); -(C₃-C₆)cycloalkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -OH, (=O); each R²¹, R²¹ᵃ, R²¹ᵇ, R²¹ᶜ, R²², R²²ᵃ, R²²ᵇ, R²²ᶜ is independently -Hal, -H, -OH, -NO₂, -NR²³R²⁴, -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals selected from -Hal, -NH₂, -O(C₁-C₆)alkyl, -OH, (=O); each R²³, R²⁴ is independently -H; -(C₁-C₆)alkyl, unsubstituted or substituted by one or more radicals selected from (=O), -OH, -NR²⁵R²⁶; -(C₂-C₆)alkenyl, unsubstituted or substituted by one or more radicals selected from (=O), -NR²⁵ᵃR²⁶ᵃ; each R²⁵, R²⁶, R²⁵ᵃ, R²⁶ᵃ is independently -H, -(C₁-C₆)alkyl; Hal is a fluorine, bromine, chlorine, or iodine atom. Claim 16: A method of inhibiting the biological activity of the epidermal growth factor receptor (EGFR) in a subject, consisting of contacting the EGFR kinase domain with a compound as claimed in any of claims 1 - 15 or its pharmacologically acceptable salt, solvate or stereoisomer. Claim 23: A method of treating a disease or disorder mediated by EGFR activity, including administration in a therapeutically effective amount of a compound as claimed in claims 1-15 or its pharmacologically acceptable salt, solvate or stereoisomer, or the pharmaceutical composition as claimed in claim 17 to a subject in need of said treatment.